Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934770 | 0.94 | ESR2 (0.35) | HSP90AB1HDAC4HDAC2HDAC8ESR2 | |
| SCHEMBL1778645 | 0.78 | KMO (0.40) | ACMSDMAPTBACE1HSP90AA1HDAC4 | |
| SCHEMBL434766 | 0.77 | CEL (0.36) | ALDH1A1 | |
| SCHEMBL434060 | 0.77 | PTGDR (0.35) | MAPT | |
| SCHEMBL7838303 | 0.77 | PTGDR2 (0.35) | ALDH1A1POLB | |
| SCHEMBL10631828 | 0.77 | CEL (0.36) | ALDH1A1 | |
| SCHEMBL433060 | 0.77 | PTGDR2 (0.35) | ALDH1A1POLB | |
| SCHEMBL1777247 | 0.77 | NPC1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL28299092 | 0.76 | HDAC8 (0.38) | ACMSDMAPTPOLBBACE1HSP90AA1 | |
| SCHEMBL9730874 | 0.74 | PTGDR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522868-B2 | Tetrakis(ether-substituted formylphenyl) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-8921613-B2 | Polynuclear poly(phenol) family | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20120277479-A1 | NOVEL POLYNUCLEAR POLY(PHENOL) FAMILY | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | AHR, PAH, ALK | HSP90AB1 4414/4885ACMSD 1029/4885ALDH1A1 1415/4885 |
| US-20120277479-A1 | NOVEL POLYNUCLEAR POLY(PHENOL) FAMILY | PAH, C1S, AP1S1 | HSP90AB1 4406/4885ACMSD 1524/4885ALDH1A1 3913/4885 |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | AHR, PAH, ARNT | HSP90AB1 3856/4885ACMSD 1637/4885ALDH1A1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.